Badanie nad HM15912 u dorosłych pacjentów z zespołem krótkiego jelita i niewydolnością jelitową

Short Bowel Syndrome-associated Intestinal Failure (SBS-IF) is a condition where the body cannot absorb enough nutrients and fluids due to a lack of sufficient small intestine. This study is focused on evaluating a new treatment called HM15912, which is a type of protein designed to help improve nutrient absorption in people with this condition. The treatment is given as an injection under the skin using a pre-filled syringe.

The main goal of the study is to check how safe and tolerable HM15912 is when given over a period of 24 weeks. Researchers will also study how the body processes the treatment. Participants will receive multiple doses of the treatment and will be monitored for any side effects or reactions at the injection site. The study will also look at changes in vital signs and other health indicators.

Throughout the study, participants will have regular check-ups to ensure their safety and to track how their bodies respond to the treatment. The study aims to provide valuable information on whether HM15912 can be a helpful option for people with SBS-IF, potentially improving their quality of life by reducing their need for additional nutrition through intravenous methods.